We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cencora Raises 2026 EPS Outlook as Specialty Businesses Strengthen
Read MoreHide Full Article
Key Takeaways
Cencora lifted fiscal 2026 adjusted EPS guidance to $17.75-$17.95 after stronger third-quarter profits.
COR's U.S. segment profit rose 15.9%, helped by OneOncology, specialty sales and higher pharma volumes.
Cencora's international operating income rose 20.8%, driven by European distribution and specialty logistics.
Cencora (COR - Free Report) raised its fiscal 2026 adjusted earnings outlook after third-quarter results showed faster profit growth across both healthcare solutions segments. Adjusted earnings per share rose 12% year over year to $4.48, topping the Zacks Consensus Estimate by 2.5%.
The investor question is whether specialty-driven operating leverage can keep outweighing lower-margin product mix and higher financing costs. Recent results suggest specialty is doing more of the earnings work, even as reported revenue growth remains pressured by pricing changes and customer losses.
Cencora’s Q3 Beat Leads to a Higher EPS Outlook
Third-quarter revenues increased 5.1% to $84.76 billion, while adjusted operating income advanced 17% to $1.24 billion. Adjusted operating margin improved 15 basis points to 1.46% as gross profit growth outpaced the increase in operating expenses.
Cencora lifted fiscal 2026 adjusted earnings guidance to $17.75-$17.95 per share from $17.70-$17.90. It also narrowed adjusted operating income growth expectations upward to 13%-14% from 12%-14%, while maintaining consolidated revenue growth guidance of 4%-6%.
Image Source: Zacks Investment Research
COR’s U.S. Healthcare Business Drives Profit Growth
U.S. Healthcare Solutions revenues rose 4.9% to $74.9 billion, supported by higher unit volumes, specialty product sales and GLP-1 demand. Segment operating income climbed 15.9% to $966.2 million, aided by OneOncology and increased pharmaceutical sales.
Management said OneOncology and Retina Consultants of America performed ahead of expectations, while the core business generated double-digit organic operating income growth excluding OneOncology and the lost oncology customer. McKesson Corporation (MCK - Free Report) is also expanding its oncology and multispecialty platform, including an agreement announced in August to acquire Precision Medicine Group for about $2.25 billion. Cardinal Health (CAH - Free Report) , another major pharmaceutical distributor, provides a useful industry comparison because pharmaceutical distribution remains central to its business.
Cencora’s International Segment Adds Momentum
International Healthcare Solutions revenues increased 5.9% to $7.7 billion, or 6.1% at constant currency. Operating income rose 20.8% to $165.9 million and advanced 23.1% at constant currency.
European distribution and global specialty logistics drove the improvement. The quarter also benefited from the timing of manufacturer price changes in a developing market, a factor management does not expect to repeat in the fourth quarter.
COR’s GLP-1 Mix and Interest Costs Temper the Upside
GLP-1 sales increased $2.3 billion year over year and supported U.S. revenue growth, but these products carry lower gross profit margins than many other categories. Cencora also absorbed a $2.4 billion revenue headwind from manufacturer list-price reductions, along with the effects of a lost oncology customer and lower sales to a large mail-order customer.
Financing is another offset. Net interest expense increased 72% to $140.7 million, primarily because of debt raised to help fund the OneOncology acquisition and lower interest income. Cencora has made progress on debt repayment, but higher borrowing costs remain part of the earnings equation.
The raised outlook and specialty execution support the earnings picture, but mix, pricing and financing pressures keep the near-term setup balanced. Cencora currently carries a Zacks Rank #3 (Hold), which points to a neutral near-term earnings-estimate signal rather than a clear buy or sell indication. McKesson and Cardinal Health currently carry a Zacks Rank of 3. You can see the complete list of today’s Zacks #1 Rank (Strong Buy)stocks here.
COR has a Growth Score of A, VGM Score of A and Value Score of B, indicating favorable characteristics across growth and broader style measures. Its Momentum Score of D is less supportive. Because Style Scores are designed to complement the Zacks Rank, the combination suggests attractive fundamental traits alongside a more measured near-term view.
View the Zacks #1 Rank List
Image: Bigstock
Cencora Raises 2026 EPS Outlook as Specialty Businesses Strengthen
Key Takeaways
Cencora (COR - Free Report) raised its fiscal 2026 adjusted earnings outlook after third-quarter results showed faster profit growth across both healthcare solutions segments. Adjusted earnings per share rose 12% year over year to $4.48, topping the Zacks Consensus Estimate by 2.5%.
The investor question is whether specialty-driven operating leverage can keep outweighing lower-margin product mix and higher financing costs. Recent results suggest specialty is doing more of the earnings work, even as reported revenue growth remains pressured by pricing changes and customer losses.
Cencora’s Q3 Beat Leads to a Higher EPS Outlook
Third-quarter revenues increased 5.1% to $84.76 billion, while adjusted operating income advanced 17% to $1.24 billion. Adjusted operating margin improved 15 basis points to 1.46% as gross profit growth outpaced the increase in operating expenses.
Cencora lifted fiscal 2026 adjusted earnings guidance to $17.75-$17.95 per share from $17.70-$17.90. It also narrowed adjusted operating income growth expectations upward to 13%-14% from 12%-14%, while maintaining consolidated revenue growth guidance of 4%-6%.
Image Source: Zacks Investment Research
COR’s U.S. Healthcare Business Drives Profit Growth
U.S. Healthcare Solutions revenues rose 4.9% to $74.9 billion, supported by higher unit volumes, specialty product sales and GLP-1 demand. Segment operating income climbed 15.9% to $966.2 million, aided by OneOncology and increased pharmaceutical sales.
Management said OneOncology and Retina Consultants of America performed ahead of expectations, while the core business generated double-digit organic operating income growth excluding OneOncology and the lost oncology customer. McKesson Corporation (MCK - Free Report) is also expanding its oncology and multispecialty platform, including an agreement announced in August to acquire Precision Medicine Group for about $2.25 billion. Cardinal Health (CAH - Free Report) , another major pharmaceutical distributor, provides a useful industry comparison because pharmaceutical distribution remains central to its business.
Cencora’s International Segment Adds Momentum
International Healthcare Solutions revenues increased 5.9% to $7.7 billion, or 6.1% at constant currency. Operating income rose 20.8% to $165.9 million and advanced 23.1% at constant currency.
European distribution and global specialty logistics drove the improvement. The quarter also benefited from the timing of manufacturer price changes in a developing market, a factor management does not expect to repeat in the fourth quarter.
COR’s GLP-1 Mix and Interest Costs Temper the Upside
GLP-1 sales increased $2.3 billion year over year and supported U.S. revenue growth, but these products carry lower gross profit margins than many other categories. Cencora also absorbed a $2.4 billion revenue headwind from manufacturer list-price reductions, along with the effects of a lost oncology customer and lower sales to a large mail-order customer.
Financing is another offset. Net interest expense increased 72% to $140.7 million, primarily because of debt raised to help fund the OneOncology acquisition and lower interest income. Cencora has made progress on debt repayment, but higher borrowing costs remain part of the earnings equation.
Cencora, Inc. Revenue (Quarterly)
Cencora, Inc. revenue-quarterly | Cencora, Inc. Quote
Cencora’s Strong Style Scores Meet a Hold Signal
The raised outlook and specialty execution support the earnings picture, but mix, pricing and financing pressures keep the near-term setup balanced. Cencora currently carries a Zacks Rank #3 (Hold), which points to a neutral near-term earnings-estimate signal rather than a clear buy or sell indication. McKesson and Cardinal Health currently carry a Zacks Rank of 3. You can see the complete list of today’s Zacks #1 Rank (Strong Buy)stocks here.
COR has a Growth Score of A, VGM Score of A and Value Score of B, indicating favorable characteristics across growth and broader style measures. Its Momentum Score of D is less supportive. Because Style Scores are designed to complement the Zacks Rank, the combination suggests attractive fundamental traits alongside a more measured near-term view.